These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 8185643)
1. Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action. Cummings J; Allan L; Smyth JF Biochem Pharmacol; 1994 Apr; 47(8):1345-56. PubMed ID: 8185643 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological determinants of the antitumour activity of mitomycin C. Spanswick VJ; Cummings J; Ritchie AA; Smyth JF Biochem Pharmacol; 1998 Dec; 56(11):1497-503. PubMed ID: 9827584 [TBL] [Abstract][Full Text] [Related]
3. Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo. Chirrey L; Cummings J; Halbert GW; Smyth JF Cancer Chemother Pharmacol; 1995; 35(4):318-22. PubMed ID: 7828274 [TBL] [Abstract][Full Text] [Related]
4. The consequences of doxorubicin quinone reduction in vivo in tumour tissue. Cummings J; Willmott N; Hoey BM; Marley ES; Smyth JF Biochem Pharmacol; 1992 Dec; 44(11):2165-74. PubMed ID: 1472081 [TBL] [Abstract][Full Text] [Related]
5. Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase. Spanswick VJ; Cummings J; Smyth JF Biochem Pharmacol; 1996 Jun; 51(12):1623-30. PubMed ID: 8687477 [TBL] [Abstract][Full Text] [Related]
6. Determination of mitomycin C, 2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumour tissue by high-performance liquid chromatography. Cummings J; Chirrey L; Willmott N; Halbert GW; Smyth JF J Chromatogr; 1993 Jan; 612(1):105-13. PubMed ID: 8454690 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. Nomura T; Saikawa A; Morita S; Sakaeda Kakutani T; Yamashita F; Honda K; Takakura Y; Hashida M J Control Release; 1998 Mar; 52(3):239-52. PubMed ID: 9743445 [TBL] [Abstract][Full Text] [Related]
8. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development. Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802 [TBL] [Abstract][Full Text] [Related]
9. Chromatographic studies of mitomycin C degradation in albumin microspheres. Mehta RC; Hogan TF; Mardmomen S; Ma JK J Chromatogr; 1988 Sep; 430(2):341-9. PubMed ID: 3148622 [TBL] [Abstract][Full Text] [Related]
10. Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Cummings J; Spanswick VJ; Tomasz M; Smyth JF Biochem Pharmacol; 1998 Aug; 56(4):405-14. PubMed ID: 9763215 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116 [TBL] [Abstract][Full Text] [Related]
12. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells. Pan SS; Yu F; Hipsher C Mol Pharmacol; 1993 Jun; 43(6):870-7. PubMed ID: 8316219 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma. Ma LW; Moan J; Steen HB; Iani V Br J Cancer; 1995 May; 71(5):950-6. PubMed ID: 7734319 [TBL] [Abstract][Full Text] [Related]
15. Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Gustafson DL; Pritsos CA Cancer Res; 1993 Nov; 53(22):5470-4. PubMed ID: 8221687 [TBL] [Abstract][Full Text] [Related]
16. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Begleiter A; Leith MK; Curphey TJ Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837 [TBL] [Abstract][Full Text] [Related]
17. Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo. Begleiter A; Leith MK; Thliveris JA; Digby T Br J Cancer; 2004 Oct; 91(8):1624-31. PubMed ID: 15467770 [TBL] [Abstract][Full Text] [Related]
18. Increased anti-tumor effect of adriamycin-loaded albumin microspheres is associated with anaerobic bioreduction of drug in tumor tissue. Willmott N; Cummings J Biochem Pharmacol; 1987 Feb; 36(4):521-6. PubMed ID: 3827939 [TBL] [Abstract][Full Text] [Related]
19. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Lukka PB; Paxton JW; Kestell P; Baguley BC Cancer Chemother Pharmacol; 2012 Jul; 70(1):151-60. PubMed ID: 22660735 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]